Compare Johnson & Johnson (JNJ) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares Ultra Gold ETF — how do they compare? Johnson & Johnson trades at $260.33 (market cap $618.09B), while ProShares Ultra Gold ETF trades at $46.57 (market cap $716.59M). The key difference: Johnson & Johnson is far larger — about 862.5× ProShares Ultra Gold ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while ProShares Ultra Gold ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and ProShares Ultra Gold ETF for 23 Days on average.
| JNJ | UGL | |
|---|---|---|
Market Cap | $618.09B | $716.59M |
Volume | 6,050,983 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $278.43 | $85.62 |
52-Week Low | $186.00 | $42.79 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
UGL trades at $46.47, up 4.59% in the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing to selling pressure. Key support lies at $44, while resistance is near $46. The stock lacks disclosed financial ratios, limiting fundamental visibility. Recent news highlights gold price volatility driven by Treasury yields and Federal Reserve policy expectations, influencing sentiment around gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds from rising rates. Investment opportunity hinges on gold price stabilization, but risks include persistent bearish indicators and sensitivity to interest rate changes. Investors should await clearer fundamental data and technical confirmation of a trend reversal before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
